Important note: Information in this article was accurate in Summer 2002. The state of the art may have changed since the publication date.
 |
Research Initiative Treatment Action (RITA!); Vol 8, No. 1 Summer 2002
Source: Ben Cheng, Project Inform *
|
Compound |
Class of Compound |
Phase of Development |
Pharmaceutical Company |
|
ACH-126,443 (L-Fd4C) |
nucleoside analog RT inhibitor |
Phase 1 |
Achilleon |
|
ADA |
zinc finger |
Phase 1 – 2 |
Hubriphar |
|
AMD-3465° |
CXCR4 antagonist |
Preclinical |
AnorMed |
|
AMD-8445° |
entry inhibitor |
Preclinical |
AnorMed |
|
Atazanavir (BMS-232623) |
protease inhibitor |
Phase 2 – 3* |
Bristol-Myers Squibb |
|
BCH-10618 (DOTC) |
nucleoside analog RT inhibitor |
Preclinical |
Shire Biochem |
|
BEA-005° |
nucleoside analog RT inhibitor |
Preclinical |
Medivir |
|
Beta-D-Fd4C° |
nucleoside analog RT inhibitor |
Preclinical |
Vion |
|
Beta-L-Fd4C° |
nucleoside analog RT inhibitor |
Preclinical |
Vion |
|
BMS-806 |
entry inhibitor |
Phase 1 |
Bristol-Myers Squibb |
|
Calanolide A |
non-nucleoside RT inhibitor |
Phase 2 |
Sarawak Medichem |
|
Capravirine |
non-nucleoside RT inhibitor |
Phase 2 |
Pfizer/Agouron |
|
DAPD |
nucleoside analog RT inhibitor |
Phase 1 – 2 |
Triangle Pharmaceuticals |
|
DEHSPM |
inhibits hypusin/eIF-5A |
Phase 1 |
SunPharm |
|
DPC 083 |
non-nucleoside RT inhibitor |
Phase 1 – 2 |
DuPont Pharmaceuticals** |
|
DPC 681 |
protease inhibitor |
Preclinical |
Dupont Pharmaceuticals** |
|
DPC 684 |
protease inhibitor |
Preclinical |
Dupont Pharmaceuticals** |
|
DPC 961 |
non-nucleoside RT inhibitor |
Phase 1 |
DuPont Pharmaceuticals** |
|
Emivirine (MKC-442) |
non-nucleoside RT inhibitor |
Phase 3 |
Triangle Pharmaceuticals |
|
Emtricitabine (FTC) |
nucleoside analog RT inhibitor |
Phase 3 |
Triangle Pharmaceuticals |
|
HI-236° |
non-nucleoside RT inhibitor |
Preclinical |
Wayne Hughes Institute |
|
Hu5A8° |
binding inhibitor |
Preclinical |
Tanox |
|
Hydroxyurea |
inhibits cellular factors |
Phase 2 – 3 |
Bristol-Myers Squibb |
|
L-870,810 |
integrase inhibitor |
Phase 1 |
Merck & Co. |
|
LB-71350° |
protease inhibitor |
Preclinical |
LG Chemical |
|
Mycophenlate |
inhibits cellular factors |
Phase 1 – 2 |
Hoffman-La Roche |
|
Peldesine |
inhibits cellular factors |
Phase 1 |
Biocryst |
|
Pentfuside (T-20) |
fusion inhibitor |
Phase 3* |
Trimeris/Roche |
|
Phosphazid° |
nucleoside analog RT inhibitor |
Preclinical |
Viscount |
|
PNU142721 |
non-nucleoside RT inhibitor |
Preclinical |
Pharmacia |
|
PRO 140 |
CCR5 antagonist |
Preclinical |
Progenics |
|
PRO 367 |
entry inhibitor |
Phase 1 |
Progenics |
|
PRO 542 |
attachment inhibitor |
Phase 1 – 2 |
Progenics |
|
RD4-2217° |
non-nucleoside RT inhibitor |
Preclinical |
Tosoh |
|
Resveratrol |
inhibits cellular factors |
Phase 1 |
Pharmascience |
|
S-1360 |
integrase inhibitor |
Phase 1 – 2 |
Shionogi Pharmaceuticals |
|
SCH C |
CCR5 antagonist |
Phase 1 |
Schering Plough |
|
SCH D |
CCR5 antagonist |
Preclinical |
Schering Plough |
|
SJ-3366° |
non-nucleoside RT inhibitor |
Preclinical |
Samjin |
|
T-1249 |
fusion inhibitor |
Phase 1 |
Trimeris/Roche |
|
TAK 449 |
CCR5 antagonist |
Preclinical |
Takeda |
|
Tipranavir |
protease inhibitor |
Phase 1 – 2 |
Boehringer Ingelheim |
|
TMC 125 |
non-nucleoside RT inhibitor |
Phase 2 |
Tibotec Virco |
|
TMC 120 |
non-nucleoside RT inhibitor |
Phase 2 |
Tibotec Virco |
|
TMC 126 |
protease inhibitor |
Phase 1 |
Tibotec Virco |
|
UC-781° |
non-nucleoside RT inhibitor |
Preclinical |
Uniroyal |
|
UK-427,857 |
CCR5 antagonist |
Preclinical |
Pfizer |
|
VX-175/GW433908 (amprenavir prodrug) |
protease inhibitor |
Phase 2 – 3 |
Vertex/GlaxoSmithKline |
* Available in expanded access
** Dupont Pharmaceuticals sold its anti-HIV drug Sustiva and its HIV research pipeline to Bristol-Myers Squibb in 2001
° No information available
* Ben Cheng is now the Project Manager at the Forum for Collaborative HIV Research in Washington, DC (hivforum.org).
20020710
RI020707
Copyright © 2002 - Research Initiative Treatment Action (RITA!). Reproduced with permission. RITA! is published by The Center for AIDS. Contact Thomas Gegeny, MS, ELS, Editor, RITA! for permission to reproduce RITA!. tom@centerforaids.org. http://www.centerforaids.org
ÆGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1985, 2002. ÆGiS . All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS , or the party credited as the provider of the content.